AlphaQuest LLC Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RARE

AlphaQuest LLC trimmed its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 30.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,642 shares of the biopharmaceutical company’s stock after selling 3,277 shares during the period. AlphaQuest LLC’s holdings in Ultragenyx Pharmaceutical were worth $278,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Ethic Inc. bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth about $241,000. Privium Fund Management B.V. boosted its stake in Ultragenyx Pharmaceutical by 1.4% in the 2nd quarter. Privium Fund Management B.V. now owns 253,304 shares of the biopharmaceutical company’s stock worth $9,185,000 after purchasing an additional 3,500 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $715,000. Nordea Investment Management AB grew its position in shares of Ultragenyx Pharmaceutical by 59.8% during the 2nd quarter. Nordea Investment Management AB now owns 60,176 shares of the biopharmaceutical company’s stock valued at $2,208,000 after purchasing an additional 22,509 shares in the last quarter. Finally, WCM Investment Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 4.1% during the 2nd quarter. WCM Investment Management LLC now owns 210,469 shares of the biopharmaceutical company’s stock valued at $7,686,000 after purchasing an additional 8,256 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

RARE has been the subject of a number of recent analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, October 8th. Canaccord Genuity Group reduced their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wedbush reduced their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating for the company in a research report on Monday, July 14th. Wells Fargo & Company initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Monday, October 20th. They set an “overweight” rating and a $65.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, September 9th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $82.27.

Ultragenyx Pharmaceutical Trading Down 1.6%

Ultragenyx Pharmaceutical stock opened at $34.60 on Friday. The firm has a 50-day moving average of $31.26 and a 200-day moving average of $32.98. The firm has a market cap of $3.33 billion, a P/E ratio of -6.26 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $53.47.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm had revenue of $166.50 million for the quarter, compared to analysts’ expectations of $161.37 million. During the same period in the previous year, the firm earned ($1.52) earnings per share. The business’s revenue was up 13.2% compared to the same quarter last year. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,942 shares of the business’s stock in a transaction on Monday, October 13th. The stock was sold at an average price of $31.51, for a total value of $250,252.42. Following the sale, the chief financial officer directly owned 98,227 shares of the company’s stock, valued at approximately $3,095,132.77. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Karah Herdman Parschauer sold 2,450 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $31.17, for a total transaction of $76,366.50. Following the sale, the executive vice president directly owned 73,271 shares of the company’s stock, valued at $2,283,857.07. This trade represents a 3.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 10,456 shares of company stock valued at $328,486 over the last 90 days. 5.50% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.